Secondary outcomes included change in nausea VAS scores at 2 hours, use of rescue medication at 2 hours, and improvement or resolution of vertigo at 1 week or 1 month. Main Outcomes and Measures The predefined primary outcome was change in 10- or 100-point vertigo or dizziness visual analog scale (VAS) scores at 2 hours after treatment.
Data were pooled using a random-effects model. Studies of healthy volunteers, prophylactic treatment, or induced vertigo were excluded, as were studies that compared 2 medications from the same class.ĭata Extraction and Synthesis Following Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines, data were extracted and risk of bias was assessed by 2 authors independently for each study. Study Selection We included randomized clinical trials (RCTs) comparing antihistamine or benzodiazepine use with another comparator, placebo, or no intervention for patients with a duration of acute vertigo for 2 weeks or less. Bibliographies of the included studies and relevant reviews were also screened. Objective To assess the efficacy of antihistamines and benzodiazepines in the treatment of acute vertigo from any underlying cause.ĭata Sources We searched the PubMed, CENTRAL, EMBASE, CINAHL, Scopus, and databases from inception to January 14, 2019, without language restrictions.
Antihistamines and benzodiazepines are frequently prescribed as “vestibular suppressants,” but their efficacy is unclear. Importance Acute vertigo can be disabling.
0 kommentar(er)
